For most people, a piece of gum is a fleeting moment of flavor. For Vishar Yaghoubian, it is a vehicle for a clinical intervention. The University of Toronto alum and her co-founder, PhD candidate Brian Webb, are building Toothpod on a simple, if ambitious, premise: that a chewable tablet can deliver measurable, research-backed oral hygiene benefits when a toothbrush is out of reach [University of Toronto]. It is a bet that oral care, a field dominated by decades-old mechanical tools, is ready for a bioactive, portable supplement.
Toothpod’s product is a mint-flavored chewable tablet, sold in 20-packs direct to consumers. The company positions it not as a replacement for brushing, but as a functional supplement for the moments in between [YouTube]. The active ingredients, which the company describes as all-natural, are formulated to offer anti-microbial, anti-inflammatory, and enamel-remineralizing properties [entrepreneurs.utoronto.ca]. For Yaghoubian, who has a background in dental training, the goal is to move beyond cavity prevention and into measurable gum health [dew.life]. The company has secured $850,000 in funding and an additional $450,000 in grants, according to public reports [Startup Story].
The Clinical Wedge
The core of Toothpod’s differentiation is its claim to be “the world’s first research-backed remineralizing chewing gum” [f4.fund]. The startup has partnered with the Harvard School of Dental Medicine to conduct a clinical trial [The Globe and Mail]. While detailed results are not yet public, the study reportedly involves 60 healthy periodontal patients in the U.S., measuring impacts on oral microbiota and enamel health [YouTube]. This scientific validation is the wedge Toothpod hopes will separate it from conventional sugar-free gums and even newer competitors like Bite or Huppy.
The Founders and Early Traction
The team is a blend of clinical aspiration and academic rigor. CEO Vishar Yaghoubian is an emerging figure in Toronto’s startup ecosystem, having won over $200,000 in prizes from more than 25 competitions [goodmanstech.ca]. She serves as an Entrepreneur in Residence at NEXT Canada [theorg.com]. Co-founder Brian Webb brings a biomedical research perspective from his PhD candidacy at the University of Toronto [Brian Webb - U Corp/Toothpod | LinkedIn].
| Founder | Role | Key Background |
|---|---|---|
| Vishar Yaghoubian | Co-Founder & CEO | Dental training; award-winning U of T entrepreneur; Entrepreneur in Residence, NEXT Canada [dew.life, goodmanstech.ca, theorg.com] |
| Brian Webb | Co-Founder | PhD candidate in biomedical engineering, University of Toronto [Brian Webb - U Corp/Toothpod |
The Path Beyond DTC
Toothpod’s current direct-to-consumer website is a starting point, but the company’s announced strategy reveals a more ambitious channel plan. It has secured an agreement to roll out its product in a major Dental Service Organization (DSO) with 400 clinics across the United States [The Globe and Mail]. Success in a clinical setting would represent a powerful endorsement, transforming the chewable from a consumer novelty into a recommended adjunct to care.
The Risks on the Shelf
- Clinical proof. The partnership with Harvard is a strong signal, but the burden of proof remains. Until peer-reviewed data is published, the specific efficacy claims rest on the credibility of the institution rather than public evidence.
- Category creation. Toothpod is not just selling gum; it is asking consumers to rethink a daily habit and pay a premium for a clinical benefit they cannot see.
- Competitive response. The oral care aisle is crowded and well-funded. Established players like Colgate or Procter & Gamble could quickly replicate a bioactive gum format if the category gains traction.
The Next Twelve Months
The coming year will be decisive for Toothpod. The key milestones are the execution of its DSO rollout and the publication of initial data from its Harvard clinical trial. Success in the dental clinics would prove its B2B model and establish professional endorsement. Concurrently, the company will likely need to raise a seed round to scale manufacturing, support broader marketing, and potentially fund additional clinical studies to expand its claims.